<DOC>
	<DOCNO>NCT01500018</DOCNO>
	<brief_summary>This single dose , crossover study ass abuse potential TC-5214 compare placebo , ketamine , phentermine healthy recreational polydrug user .</brief_summary>
	<brief_title>Study Healthy Recreational Polydrug Users Measure Abuse Potential TC-5214</brief_title>
	<detailed_description>A Single-center , Single-dose , Double-blind , Randomized , Placebo- Active-controlled Crossover Study Evaluate Abuse Potential TC-5214 Healthy Recreational Polydrug Users .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Phentermine</mesh_term>
	<criteria>Current recreational polydrug user experience least 2 drug class abuse . At least 10 lifetime us stimulant drug ( eg , amphetamine , cocaine , methamphetamine ) 10 lifetime occasion recreational use psychedelic drug ( eg , cannabis , ketamine , dextromethorphan , PCP , MDMA [ ecstasy ] , LSD , mesacline , psilocybin ) . Recreational use class drug permit , include opioids ( eg , codeine , morphine , heroin ) , minor tranquilizer , sedative ( eg , benzodiazepine barbiturate ) . Male female volunteer age 18 55 , inclusive body mass index ( BMI ) within range 19.0 33.0 kg/m2 , inclusive , minimum weight 50.0 kg screening . Must pas qualification phase eligibility criterion . Selfreported history drug alcohol dependence ( except caffeine ) past 12 month , include subject ever drug rehabilitation program ( treatment smoke cessation ) . Unwillingness inability abstain recreational drug use duration study screen followup . Positive hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) screen . Any significant unstable hepatic , renal , pulmonary , cardiovascular , ophthalmologic , neurologic , medical condition might confound study put volunteer great risk study participation . Currently smoke 20 cigarette ( 2 cigar ) per day , and/or unwillingness abstain smoking duration least 12 hour . Use tobacco cessation product within 1 month ( eg , nicotine substitution product , bupropion , etc ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Phase I</keyword>
	<keyword>healthy recreational polydrug user</keyword>
	<keyword>abuse liability</keyword>
	<keyword>TC-5214</keyword>
	<keyword>Single dose crossover study evaluate abuse potential TC-5214</keyword>
</DOC>